tiprankstipranks
Advertisement
Advertisement

Telomir Pharmaceuticals to participate in BIO 2025 in Boston

Telomir Pharmaceuticals (TELO) announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions. Telomir is actively preparing to submit an Investigational New Drug application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1